Objectives
After participating in this educational activity, attendees should be able to:
- Discuss the unique properties of Buprenorphine XR (BUP XR)
- Review clinical indications/when to consider BUP XR
- Review practical administrative and clinical considerations
- Discuss real world application through the use of case examples
Faculty
Laura Kehoe, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Medical Director, Massachusetts General Hospital Substance Use Disorder Bridge Clinic
Faculty Disclosure
The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Accreditation Statement
In support of improving patient care, Baystate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician
Baystate Continuing Interprofessional Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
- 1.25 AMA PRA Category 1 Credit™
- 1.25 BCIPE Instructional Hours